Breaking News: Chemesis International Inc. Closes Acquisition of La Finca Interacviva-Arachna Med

Chemesis International Inc. (OTC: CADMF) (CSE: CSI) is pleased to announce that it has entered into a definitive agreement for the acquisition of 100% of La Finca Interacviva-Arachna Med SAS (“La Finca”), an integrated cannabis company that has been operational since late 2017 and which has CAD $2,300,000 in working capital on hand.

Chemesis believes the emerging Latin American market is poised for major growth. The LATAM Cannabis Report estimates the region will have a market value of US $4.2 billion by the year 2028. Furthermore, the report expects Colombia to have a market value of US $664 million in the same time frame. Colombia’s large market value is attributed to its large population, cost efficiency, and free trade agreements with countries around the world. 1

“With the completion of this acquisition, Chemesis will significantly increase its footprint in Latin America,” said Edgar Montero, CEO of Chemesis. “The Company believes its exposure in Latin America will not only provide access to more opportunities in the region, but internationally as well. La Finca is ramping up as planned and has submitted all necessary documents to the Ministry of Justice to expand its cultivation area to 1,060 acres.”

La Finca has made significant headway in its operations and regulatory approvals since the Company announced its intention to acquire 100% of the Colombia based company. In addition to the previously announced partnerships with Universidad Nacional de Colombia and Universidad Distrital Francisco José de Caldas, La Finca is also in discussion to partner with two other major Universities in Colombia that have been authorized by the Colombian Government to conduct cannabis research, develop seed strains, and other agronomical research.

La Finca is also in conversations with a major international lab that prepares compounding formulations for international markets and currently has operations in Colombia and 34 other countries.

To complete the acquisition, the Company is issuing CDN $8,000,000 in stock at a deemed price of CDN $1.25 per share and is agreeing to pay a further CDN $5,500,000 within the next 24 months. The stock issued is subject to 36-month contractual escrow agreement.

Sponsored Content Release. Click for Full Disclosure

  1. Dave Kranzler 6 months ago

    the Latin American market is a billion dollar industry, Chemesis is making the right move by integrating their brand there now

    • Kaelynn Morris 6 months ago

      It’s been a busy five years for Latin America’s involvement in the #cannabis market, and 2019 is going to get even busier.

  2. Martin Giles 6 months ago

    As normalization of #cannabis medicines begins to spread in Latin America, regional areas, previously run by drug lords and rebel groups, will begin to reap the benefits of a regulated system that allows them to earn a legal and sustainable living.

Leave a Comment

  • Sponsored Content Release, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, creates 100% unique original content. also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

    Please Note: is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on (the ‘Site’) is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content),, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. receives fees for producing and presenting high quality and sophisticated content on along with other financial news PR media services. does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For chemesis international inc. financial news dissemination and PR services, has been compensated five thousand dollars by the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. will always disclose any compensation in securities or cash payments for financial news PR advertising. does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security., members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: